A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer

References 18

1. 1.

   Bradbeer J. W., Kyngdon J. Primary treatment of breast cancer in elderly women with Tamoxifen. Clin Oncol. 1983;9(1):31-34.

   Not in our library

2. 2.

   Christiansen C., Christensen M. S., Transbøl I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet. 1981;1(8218):459-461.

   Not in our library10.1016/s0140-6736(81)91848-1

3. 3.

   Christiansen C., Rödbro P. Long-term reproducibility of bone mineral content measurements. Scand J Clin Lab Invest. 1977;37(4):321-323.

   Not in our library10.3109/00365517709092636

4. 4.
   A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 · 1971

   No notice
5. 5.

   De Waard F., Wang D. Y. Epidemiology and prevention: workshop report. Eur J Cancer Clin Oncol. 1988;24(1):45-48.

   Not in our library10.1016/0277-5379(88)90174-5

6. 6.

   Fentiman I. S., Powles T. J. Tamoxifen and benign breast problems. Lancet. 1987;2(8567):1070-1072.

   Not in our library10.1016/s0140-6736(87)91491-7

7. 7.

   Fornander T., Rutqvist L. E., Cedermark B., Glas U., Mattsson A., Silfverswärd C., Skoog L., Somell A., Theve T., Wilking N. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989;1(8630):117-120.

   Not in our library10.1016/s0140-6736(89)91141-0

8. 8.

   Gottardis M. M., Robinson S. P., Satyaswaroop P. G., Jordan V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 1988;48(4):812-815.

   Not in our library

9. 9.

   Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet. 1988;2(8610):563-563.

   Not in our library10.1016/s0140-6736(88)92675-x

10. 10.

    Jordan V. C. Comparative antioestrogen action in experimental breast cancer. Adv Exp Med Biol. 1981;138:165-178.

    Not in our library10.1007/978-1-4615-7192-6_10

11. 11.

    Jordan V. C., Fritz N. F., van Beurden M. Prophylactic tamoxifen. Lancet. 1986;1(8486):910-910.

    Not in our library10.1016/s0140-6736(86)91012-3

12. 12.

    Jordan V. C. Tamoxifen and endometrial cancer. Lancet. 1988;2(8618):1019-1019.

    Not in our library10.1016/s0140-6736(88)90765-9

13. 13.

    MACMAHON B., FEINLEIB M. Breast cancer in relation to nursing and menopausal history. J Natl Cancer Inst. 1960;24:733-753.

    Not in our library10.1093/jnci/24.3.733

14. 14.

    Miller A. B., Bulbrook R. D. The epidemiology and etiology of breast cancer. N Engl J Med. 1980;303(21):1246-1248.

    Not in our library10.1056/nejm198011203032130

15. 15.

    Rose D. P., Boyar A. P., Cohen C., Strong L. E. Effect of a low-fat diet on hormone levels in women with cystic breast disease. I. Serum steroids and gonadotropins. J Natl Cancer Inst. 1987;78(4):623-626.

    Not in our library

16. 16.

    Rössner S., Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis. 1984;52(3):339-346.

    Not in our library10.1016/0021-9150(84)90064-9

17. 17.

    Sakai F., Cheix F., Clavel M., Colon J., Mayer M., Pommatau E., Saez S. Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J Endocrinol. 1978;76(2):219-226.

    Not in our library10.1677/joe.0.0760219

18. 18.

    Tokunaga M., Norman J. E., Asano M., Tokuoka S., Ezaki H., Nishimori I., Tsuji Y. Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950-74. J Natl Cancer Inst. 1979;62(6):1347-1359.

    Not in our library

Cited by papers we hold 3

• Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis · 2016
  No notice
• The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice · 2013
  No notice
• Granulosa cell tumor of the ovary and antecedent of adjuvant tamoxifen use for breast cancer · 2010
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.